Growth Capital • Medical Products

Ampersand Capital Partners and Symmetric Capital Invest In Biomedical Structures

On May 24, 2010, growth capital firm Ampersand Capital Partners and private equity firm Symmetric Capital invested in medical products company Biomedical Structures

Investment Context
  • This is Ampersand Capital Partners’ 7th and Symmetric Capital’s 2nd transaction in the Medical Products sector.
  • This is Ampersand Capital Partners’ 21st and Symmetric Capital’s 10th transaction in the United States.
  • This is Ampersand Capital Partners’ 1st and Symmetric Capital’s 1st transaction in Rhode Island.
Investment Fate
  • Biomedical Structures was sold to a strategic buyer in 2016.

Explore All 336 Growth Capital Medical Products Deals - Search the Database Free


Investment Summary

Date May 24, 2010
Target Biomedical Structures
Sector Medical Products
Investor(s) Ampersand Capital Partners
Symmetric Capital
Deal Type Growth Capital

Target Company

Biomedical Structures

Warwick, Rhode Island, United States
Biomedical Structures LLC is a developer and manufacturer of biomedical textile implants, while MPC focuses on the development and manufacturing of precise polymer components.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investors Overview 2

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Deal Context for Investor #
Overall 21 of 86
Sector: Medical Products 7 of 18
Type: Growth Capital 3 of 25
State: Rhode Island 1 of 1
Country: United States 21 of 70
Year: 2010 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-04-15 Signature Genomic Laboratories

Spokane, Washington, United States

Signature Genomic Laboratories, LLC is a provider of microarray-based cytogenetic diagnostics with its proprietary SignatureChip and is the major in providing microarray-based chromosome analysis.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-08 K-TEK

Prairieville, Louisiana, United States

K-TEK Corp. is a manufacturer, and supplies level instrumentation for liquid and bulk solids detection in North America.

Sell -
Investor

Symmetric Capital

Burlington, Massachusetts, United States

Investor Investor Investor


Category Private Equity Firm
Founded 2007
PE ASSETS 202M USD
Size Small
Type Sector Agnostic
DESCRIPTION

Symmetric Capital is a private equity firm that invests in profitable growth companies in the US and Canada. Symmetric seeks to invest $5 to $25 million to help fund shareholder liquidity needs, growth, acquisitions, or debt reduction. Symmetric will consider majority or minority positions and typically looks for market-leading companies owned by their founders, a family, or small partnership. Sectors of interest include business services, healthcare and life sciences, software, IT services, applied technology, industrial products, education, logistics and distribution, and consumer products. Symmetric was formed in 2007 and is based in Waltham, Massachusetts.


Deal Context for Investor #
Overall 11 of 13
Sector: Medical Products 2 of 2
Type: Growth Capital 4 of 4
State: Rhode Island 1 of 1
Country: United States 10 of 12
Year: 2010 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-31 gryphon.ai

Boston, Massachusetts, United States

gryphon.ai is a provider of sales performance management and compliance software. The Company offers an enterprise-grade computer telephony integration platform that automatically screens, collects, and analyzes phone-based sales activity data from any device to transform activity into accurate, actionable sales insight that drives improved sales performance for many of the country’s top consumer-facing companies. gryphon.ai was founded in 1998 and is based in Boston, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-07-08 K-TEK

Prairieville, Louisiana, United States

K-TEK Corp. is a manufacturer, and supplies level instrumentation for liquid and bulk solids detection in North America.

Sell -